Should warfarin be discontinued before a dental extraction? A decision-tree analysis

被引:15
作者
Balevi, Ben [1 ]
机构
[1] Univ British Columbia, Fac Med, Vancouver, BC V5Z 1M9, Canada
来源
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY | 2010年 / 110卷 / 06期
关键词
ORAL ANTICOAGULANTS; PERIOPERATIVE MANAGEMENT; SURGERY; THERAPY;
D O I
10.1016/j.tripleo.2010.03.018
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective. The aim of this study was to determine if warfarin should be withdrawn before a single tooth extraction on a patient with a prosthetic heart valve. Study design. A quantitative decision tree was constructed to assess the expected utility values of 2 typical strategies to manage the dental extraction on a patient currently medicated with warfarin. Probabilities and utilities for a cardiovascular accident and major bleeding from a dental extraction were taken from the literature. Results. The decision slightly favors withholding warfarin: generating an optimal expected utility value of 0.976 utile. This was only 0.02 utile higher than the alternative option of continuing warfarin for a dental extraction. Conclusion. The decision to withhold or continue warfarin before a dental extraction depends more on the relative risk of a major bleeding between the 2 medical management strategies than on the consequences of a cardiovascular accident. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:691-697)
引用
收藏
页码:691 / 697
页数:7
相关论文
共 25 条
[21]  
Peltola Petteri, 2004, Gerodontology, V21, P93, DOI 10.1111/j.1741-2358.2004.00012.x
[22]   Guidelines for the management of patients on oral anticoagulants requiring dental surgery [J].
Perry, D. J. ;
Noakes, T. J. C. ;
Helliwell, P. S. .
BRITISH DENTAL JOURNAL, 2007, 203 (07) :389-393
[23]  
Robinson A, 2001, J Health Serv Res Policy, V6, P92, DOI 10.1258/1355819011927288
[24]   Bleeding after dental extractions in patients taking warfarin [J].
Salam, S. ;
Yusuf, H. ;
Milosevic, A. .
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2007, 45 (06) :463-466
[25]  
*SDI, 2009, TOP BRAND DRUGS PRES